The setback suffered in the file is naproxcinod
yet 17% plunge NicOx Monday afternoon to 2.33
Euro. Over the last five sessions, the title of
Pharmaceutical Society has lost two thirds of its
value to fall back on historically low levels.
It will go into effect at least six years ago
to find a course in as little meeting.
After the semi-defeat of its anti-inflammatory for
treatment of osteoarthritis, following a negative opinion
panel of experts from the FDA, analysts revise their
valuation model. NicOx has been this morning
degradation of two brokers.
The CM-CIC Securities has gone from "Buy" to "Sell" with
a target price revised downward very sharply to 2 euros
cons ... 16 euros previously. In turn, Aurel
lowered its opinion of "Hold" to "Sell" with a
price target cut to € 2 cons 6 euros earlier.
Aucun commentaire:
Enregistrer un commentaire